Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Coagulation Factor X
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Details : Coagadex (Coagulation Factor X) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Factor X Deficiency.
Product Name : Coagadex
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 08, 2025
Lead Product(s) : Coagulation Factor X
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor X (Human),Coagulation Factor X
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BPL Receives Orphan Drug Marketing Authorization for Coagadex® in Mexico
Details : Coagadex® is the first and only treatment specifically for Hereditary Factor X Deficiency, a very rare inherited clotting disorder that causes problems with blood clotting due to not having enough Factor X in the blood.
Product Name : Coagadex
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Coagulation Factor X (Human),Coagulation Factor X
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable